Verici Dx plc

("Verici Dx" or the "Company")

Publication of Circular

& Notice of General Meeting

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that a Circular has been published containing a notice of a general meeting to be held at the offices of Shoosmiths LLP at 1 Bow Churchyard, London, EC4M 9DQ at 11:30 a.m. on 22 June 2026 ("General Meeting").

The General Meeting is being held to ensure that the Company has sufficient authority to issue and allot new Ordinary Shares on a non-pre-emptive basis following the Fundraising announced on 5 June 2026.

The Circular and Notice of General Meeting has been posted to Shareholders and is available on the Company's website at:

https://vericidx.com/investors/documents/

Unless otherwise defined, all definitions used in this announcement will have the same meaning as described in the Circular.

Enquires:

Verici Dx

Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analysis with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence.

Operating at the intersection of laboratory and data science, Verici Dx develops complex models that answer the clinical questions that matter most with unrivaled clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx's lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection.

The company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericidx.com/ and follow us on LinkedIn.